CLINICAL STUDY: CHRONIC CORONARY ARTERY DISEASE
Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary disease, including very elderly patients
Chloe A. Allen Maycock, RN, BSN*,
Joseph B. Muhlestein, MD, FACC* ,*,
Benjamin D. Horne, MPH*,
John F. Carlquist, PhD*,
Tami L. Bair, BS*,
Robert R. Pearson, BS*,
Qunyu Li, MD*,
Jeffrey L. Anderson, MD, FACC* Intermountain Heart Collaborative Study
* LDS Hospital, Salt Lake City, Utah, USA
University of Utah, Salt Lake City, Utah, USA
Manuscript received February 26, 2002;
revised manuscript received July 23, 2002,
accepted August 1, 2002.
* Reprint requests and correspondence: Dr. Joseph B. Muhlestein, Director of Cardiology Research, LDS Hospital, 8th Avenue & C Street, Salt Lake City, Utah, USA 84143.
ldbmuhle{at}ihc.com
OBJECTIVES: This study evaluated the effect of statin therapy on mortality in individuals with significant coronary artery disease (CAD) stratified by age.
BACKGROUND: Hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) significantly reduce morbidity and mortality in individuals with CAD. Unfortunately, the large statin trials excluded individuals over 80 years old, and it is therefore unknown whether very elderly individuals benefit from statins as do younger individuals.
METHODS: A cohort of 7,220 individuals with angiographically defined significant CAD ( 70%) was included. Statin prescription was determined at hospital discharge. Patients were followed up for 3.3 ± 1.8 years (maximum 6.8). Patients were grouped by age (<65, 65 to 79, and 80 years) to determine whether statin therapy reduced mortality in an age-dependent manner.
RESULTS: Average age was 65 ± 12 years; 74% were male; and 31% had a postmyocardial infarction status. Overall mortality was 16%. Elderly patients were significantly less likely to receive statins than younger patients (80 years: 19.8%; 65 to 79 years: 21.1%; <65 years: 28.0%; p < 0.001). Mortality was decreased among statin recipients in all age groups: 80 years: 29.5% among patients not taking a statin versus 8.5% of those taking a statin (adjusted hazard ratio [HR] 0.50, p = 0.036); 65 to 79 years: 18.7% vs. 6.0% (HR 0.56, p < 0.001); and <65 years: 8.9% vs. 3.1% (HR 0.70, p = 0.097).
CONCLUSIONS: Statin therapy is associated with reduced mortality in all age groups of individuals with significant CAD, including very elderly individuals. Although older patients were less likely to receive statin therapy, they received a greater absolute risk reduction than younger individuals. More aggressive statin use after CAD diagnosis may be indicated, even in older patients.
|
Abbreviations and Acronyms
| | CABG | | coronary artery bypass graft surgery | | CAD | | coronary artery disease | | CHF | | congestive heart failure | | CI | | confidence interval | | CK-MB | | creatine kinase-MB fraction | | HR | | hazard ratio | | MI | | myocardial infarction | | PCI | | percutaneous coronary intervention |
|
This article has been cited by other articles:
|
|
|
|
 
C. R. Rahilly-Tierney, E. V. Lawler, R. E. Scranton, and J. M. Gaziano
Cardiovascular Benefit of Magnitude of Low-Density Lipoprotein Cholesterol Reduction: A Comparison of Subgroups by Age
Circulation,
October 13, 2009;
120(15):
1491 - 1497.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Shalev, G. Chodick, H. Silber, E. Kokia, J. Jan, and A. D. Heymann
Continuation of Statin Treatment and All-Cause Mortality: A Population-Based Cohort Study
Arch Intern Med,
February 9, 2009;
169(3):
260 - 268.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Li, Y. Han, W. Pang, C. Li, X. Xie, J. Y.-J. Shyy, and Y. Zhu
AMP-Activated Protein Kinase Promotes the Differentiation of Endothelial Progenitor Cells
Arterioscler Thromb Vasc Biol,
October 1, 2008;
28(10):
1789 - 1795.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Mittnacht, M. Fanshawe, and S. Konstadt
Anesthetic Considerations in the Patient With Valvular Heart Disease Undergoing Noncardiac Surgery
Seminars in Cardiothoracic and Vascular Anesthesia,
March 1, 2008;
12(1):
33 - 59.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. Afilalo, G. Duque, R. Steele, J. W. Jukema, A. J.M. de Craen, and M. J. Eisenberg
Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis.
J. Am. Coll. Cardiol.,
January 1, 2008;
51(1):
37 - 45.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. de Lusignan, J. Belsey, N. Hague, N. Dhoul, and J. van Vlymen
Audit-based education to reduce suboptimal management of cholesterol in primary care: a before and after study
J. Public Health Med.,
December 1, 2006;
28(4):
361 - 369.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Tovar and D. B. Schering
Management of Dyslipidemia in Special Populations
Journal of Pharmacy Practice,
April 1, 2006;
19(2):
63 - 78.
[Abstract]
[PDF]
|
|
|
|
|
|
|
J. G. Ray, Y. Gong, K. Sykora, and J. V. Tu
Statin Use and Survival Outcomes in Elderly Patients With Heart Failure
Arch Intern Med,
January 10, 2005;
165(1):
62 - 67.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. T. Montero, J. Matilla, E. Gomez-Mampaso, and M. A. Lasuncion
Geranylgeraniol Regulates Negatively Caspase-1 Autoprocessing: Implication in the Th1 Response against Mycobacterium tuberculosis
J. Immunol.,
October 15, 2004;
173(8):
4936 - 4944.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Lappe, J. B. Muhlestein, D. L. Lappe, R. S. Badger, T. L. Bair, R. Brockman, T. K. French, L. C. Hofmann, B. D. Horne, S. Kralick-Goldberg, et al.
Improvements in 1-Year Cardiovascular Clinical Outcomes Associated with a Hospital-Based Discharge Medication Program
Ann Intern Med,
September 21, 2004;
141(6):
446 - 453.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. R Last
Review: smoking cessation reduces the risk of death and non-fatal myocardial infarction in coronary heart disease
Evid. Based Med.,
January 1, 2004;
9(1):
28 - 28.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. A Dornbrook-Lavender, M. T Roth, and J. A Pieper
Secondary Prevention of Coronary Heart Disease in the Elderly
Ann. Pharmacother.,
December 1, 2003;
37(12):
1867 - 1876.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Maurer
Age: a nonmodifiable risk factor?
J. Am. Coll. Cardiol.,
October 15, 2003;
42(8):
1427 - 1428.
[Full Text]
[PDF]
|
|
|
|
